ATG16L1

Across TCGA pan-cancer cohorts, ATG16L1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG16L1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ATG16L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATG16L1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

COAD, LIHC, and PRAD are the cancer types where ATG16L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.208	0.791	.008	21	view →
LIHC	DFS	Median	III,IV	0.079	0.333	.009	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.910	0.618	.032	4	view →
SKCM	OS	Median	II,III,IV	1.000	0.374	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG16L1–COAD (OS)

Open the COAD breakdown →